Suven Life Sciences gets 3 patents in Canada, China, India

Pharmaceutical firm Suven Life has received three product patents in Canada, China and India for its new chemical entities for treatment of disorders associated with neurodegenerative diseases.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and these patents are valid through 2025, the company said in a filing to the BSE today.

Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

These new chemical entities are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, the filing said.

With these new patents, the company has a total of 14 granted patents from Canada, 12 from China and 17 from India.

Products out of these inventions may be out-licensed at various phases of clinical development, the company said.


  • The govt should build on the feel good season to bolster its economic agenda

    There are two pieces of good news to ring in the festive season beginning this Dusshera.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Sachin Shridhar

Reordering the world order on cheap money

When you produce something, just about anything, capital is ...

Rajgopal Nidamboor

Of archetypes, not stereotypes

It is not that devising technologies, or progress, is a ...

Dharmendra Khandal

Use technology wisely to save earth's treasures

Wildlife biologists are certainly getting inspired by our armed forces’ ...


William D. Green

Chairman & CEO, Accenture